Bullous pemphigoid associated with dipeptidyl peptidase‐4 inhibitors. A case series and analysis of cases reported in the Spanish pharmacovigilance database

Association of Dipeptidyl Peptidase 4 Inhibitor Use With Risk of Bullous Pemphigoid in Patients With Diabetes

(2019) Seon Gu Lee et al.   JAMA Dermatology

Assessment of the Prevalence of Mucosal Involvement in Bullous Pemphigoid

(2019) Khalaf Kridin et al.   JAMA Dermatology

Epitope‐spreading phenomena in dipeptidyl peptidase‐4 inhibitor‐associated bullous pemphigoid

(2019) I. García‐Díez et al.   BRITISH JOURNAL OF DERMATOLOGY

Detection of anti-BP180 NC16A autoantibodies after the onset of dipeptidyl peptidase-IV inhibitor-associated bullous pemphigoid: a report of three patients

(2018) Y. Mai et al.   BRITISH JOURNAL OF DERMATOLOGY

Unique clinical and serological features of bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors

(2018) H. Horikawa et al.   BRITISH JOURNAL OF DERMATOLOGY

Bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors. Eight cases with clinical and immunological characterization

(2018) Irene García-Díez et al.   INTERNATIONAL JOURNAL OF DERMATOLOGY

Decrease in eosinophils infiltrating into the skin of patients with dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid

(2018) Chika Chijiwa et al.   JOURNAL OF DERMATOLOGY

Vildagliptin Significantly Increases the Risk of Bullous Pemphigoid: A Finnish Nationwide Registry Study

(2018) Outi Varpuluoma et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Oral diabetes medications other than dipeptidyl peptidase-4 inhibitors are not associated with bullous pemphigoid: a Finnish nationwide case control study

(2018) O. Varpuluoma et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Detection and characterization of IgG, IgE, and IgA autoantibodies in patients with bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors

(2018) Luca Fania et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: Retrospective multicenter case-control study from France and Switzerland

(2018) Michael Benzaquen et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Association of Bullous Pemphigoid With Dipeptidyl-Peptidase 4 Inhibitors in Patients With Diabetes

(2018) Khalaf Kridin et al.   JAMA Dermatology

Higher frequency of dipeptidyl peptidase IV inhibitor intake in bullous pemphigoid patients than in the French general population

(2018) Marthe Plaquevent et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Comment on “Oral diabetes medications other than dipeptidyl peptidase-4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case control study”

(2018) Khalaf Kridin   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Emerging roles of sodium–glucose cotransporter 2 inhibitors in cardiology

(2017) Atsushi Tanaka et al.   Journal of Cardiology

Multimorbidity in bullous pemphigoid: a case-control analysis of bullous pemphigoid patients with age- and gender-matched controls

(2017) B. Sim et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Linagliptin-associated bullous pemphigoid that was most likely caused by IgG autoantibodies against the midportion of BP180

(2016) A. Sakai et al.   BRITISH JOURNAL OF DERMATOLOGY

Bullous pemphigoid and dipeptidyl peptidase IV inhibitors: a case-noncase study in the French Pharmacovigilance Database

(2016) J. Béné et al.   BRITISH JOURNAL OF DERMATOLOGY

Three Cases of Bullous Pemphigoid Associated with Dipeptidyl Peptidase-4 Inhibitors - One due to Linagliptin

(2016) Francisco Manuel Ildefonso Mendonça et al.   DERMATOLOGY

Dipeptidyl peptidase-IV inhibitors induced bullous pemphigoid: a case report and analysis of cases reported in the European pharmacovigilance database

(2016) M. García et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Bullous Pemphigoid Associated With Linagliptin Treatment

(2016) Roger Haber et al.   JAMA Dermatology

Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology

(2015) C. Feliciani et al.   BRITISH JOURNAL OF DERMATOLOGY

Bullous pemphigoid induced by vildagliptin: a report of three cases

(2014) Johana Béné et al.   FUNDAMENTAL & CLINICAL PHARMACOLOGY

Inhibition of CD26/Dipeptidyl Peptidase IV Enhances CCL11/Eotaxin-Mediated Recruitment of Eosinophils In Vivo

(2014) U. Forssmann et al.   JOURNAL OF IMMUNOLOGY

Drug-induced pemphigoid: a review of the literature

(2014) P.G. Stavropoulos et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

A Case Report of Bullous Pemphigoid Induced by Dipeptidyl Peptidase-4 Inhibitors

(2013) Iman Aouidad et al.   JAMA Dermatology

Pemphigoid diseases

(2012) Enno Schmidt et al.   LANCET

Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database

(2011) Jean-Louis Montastruc et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Dipeptidyl Peptidase-4 Inhibitors Cause Bullous Pemphigoid in Diabetic Patients: Report of Two Cases

(2011) Efi Pasmatzi et al.   DIABETES CARE

Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin

(2011) K. Skandalis et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY